Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $5.32 in the prior trading day, Editas Medicine Inc (NASDAQ: EDIT) closed at $5.37, up 0.94%. In other words, the price has increased by $0.94 from its previous closing price. On the day, 1.26 million shares were traded. EDIT stock price reached its highest trading level at $5.54 during the session, while it also had its lowest trading level at $5.305.
Ratios:
Our goal is to gain a better understanding of EDIT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.39 and its Current Ratio is at 5.39. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 18, 2023, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 05 ’24 when O’Neill Gilmore Neil sold 77,824 shares for $9.42 per share. The transaction valued at 732,884 led to the insider holds 327,470 shares of the business.
Mei Baisong sold 20,327 shares of EDIT for $191,425 on Mar 04 ’24. The SVP, CHIEF MEDICAL OFFICER now owns 141,543 shares after completing the transaction at $9.42 per share. On Dec 05 ’23, another insider, Eaton Bruce, who serves as the EVP, CBO AND CTO of the company, sold 103 shares for $10.90 each. As a result, the insider received 1,122 and left with 74,791 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 441600352 and an Enterprise Value of 152765376. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.65 while its Price-to-Book (P/B) ratio in mrq is 1.26. Its current Enterprise Value per Revenue stands at 1.955 whereas that against EBITDA is -0.937.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.07, which has changed by -0.317662 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $11.91, while it has fallen to a 52-week low of $5.11. The 50-Day Moving Average of the stock is -28.73%, while the 200-Day Moving Average is calculated to be -35.43%.
Shares Statistics:
The stock has traded on average 1.92M shares per day over the past 3-months and 1668010 shares per day over the last 10 days, according to various share statistics. A total of 81.77M shares are outstanding, with a floating share count of 81.24M. Insiders hold about 1.21% of the company’s shares, while institutions hold 77.74% stake in the company. Shares short for EDIT as of 1713139200 were 18758847 with a Short Ratio of 9.79, compared to 1710460800 on 13926987. Therefore, it implies a Short% of Shares Outstanding of 18758847 and a Short% of Float of 28.92.
Earnings Estimates
The dynamic stock of Editas Medicine Inc (EDIT) is currently being evaluated by a team of 14.0 analysts, each contributing to its current rating.On average, analysts expect EPS of -$0.67 for the current quarter, with a high estimate of -$0.44 and a low estimate of -$1.09, while EPS last year was -$0.71. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.46 and low estimates of -$1.11.
Analysts are recommending an EPS of between -$1.84 and -$3.83 for the fiscal current year, implying an average EPS of -$2.66. EPS for the following year is -$2.74, with 15.0 analysts recommending between -$1.72 and -$4.51.
